Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8461563 | 0.87 | MAPT (0.35) | CA1CA2 | |
| SCHEMBL9626474 | 0.78 | MAPT (0.52) | CA1CA2CYP1A2CYP2D6PMP22 | |
| SCHEMBL12981369 | 0.78 | ALDH1A1 (0.44) | GSK3BCYP2D6 | |
| SCHEMBL2012718 | 0.76 | CES2 (0.42) | CA1CA2 | |
| SCHEMBL2017897 | 0.76 | CES2 (0.42) | CA1CA2 | |
| SCHEMBL693987 | 0.75 | SMN1; SMN2 (0.50) | CYP2D6 | |
| SCHEMBL14530150 | 0.74 | TSHR (0.55) | TPMTCA1CA2 | |
| SCHEMBL19675411 | 0.74 | MEN1 (0.55) | — | |
| Hydrogen Sulfide SCHEMBL29028321 | 0.73 | SMN1; SMN2 (0.48) | CYP2D6 | |
| SCHEMBL24905722 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509946-B1 | SPIRO INDOLE-CYCLOPROPANE INDOLINONES USEFUL AS AMPK MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-04-16 | — | — | EP | disclosed |
| US-20130102604-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8354443-B2 | Cyclopropane indolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2509946-A1 | SPIRO INDOLE - CYCLOPROPANE INDOLINONES USEFUL AS AMPK MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| CN-102656147-A | Spiro indole-cyclopropane indolinones useful as AMPK modulators | HOFFMANN LA ROCHE | 2012-09-05 | — | — | CN | disclosed |
| WO-2011069298-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070039-A1 | SPIRO INDOLE - CYCLOPROPANE INDOLINONES USEFUL AS AMPK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011069298-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| US-20110144106-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144106-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | GPR119, CPT1A, IRS1 | TPMT 3431/4885GSK3B 1183/4885CA1 3275/4885 |
| US-20130102604-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | GPR119, CPT1A, IRS1 | TPMT 3390/4885GSK3B 1209/4885CA1 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.